- Home
- FAX vs CRMD Comparison
FAX vs CRMD Comparison
Compare FAX & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAX
- CRMD
- Stock Information
- Founded
- FAX 1986
- CRMD 2006
- Country
- FAX United States
- CRMD United States
- Employees
- FAX N/A
- CRMD N/A
- Industry
- FAX Investment Managers
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- FAX Finance
- CRMD Health Care
- Exchange
- FAX Nasdaq
- CRMD Nasdaq
- Market Cap
- FAX 629.1M
- CRMD 753.6M
- IPO Year
- FAX N/A
- CRMD 2010
- Fundamental
- Price
- FAX $15.55
- CRMD $10.40
- Analyst Decision
- FAX
- CRMD Strong Buy
- Analyst Count
- FAX 0
- CRMD 6
- Target Price
- FAX N/A
- CRMD $15.67
- AVG Volume (30 Days)
- FAX 833.6K
- CRMD 1.5M
- Earning Date
- FAX 01-01-0001
- CRMD 03-11-2025
- Dividend Yield
- FAX 12.09%
- CRMD N/A
- EPS Growth
- FAX N/A
- CRMD N/A
- EPS
- FAX N/A
- CRMD N/A
- Revenue
- FAX N/A
- CRMD $12,262,234.00
- Revenue This Year
- FAX N/A
- CRMD N/A
- Revenue Next Year
- FAX N/A
- CRMD $246.41
- P/E Ratio
- FAX N/A
- CRMD N/A
- Revenue Growth
- FAX N/A
- CRMD 41184.20
- 52 Week Low
- FAX $2.33
- CRMD $2.89
- 52 Week High
- FAX $2.84
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- FAX 59.01
- CRMD 40.80
- Support Level
- FAX $15.40
- CRMD $11.90
- Resistance Level
- FAX $15.57
- CRMD $12.67
- Average True Range (ATR)
- FAX 0.15
- CRMD 0.73
- MACD
- FAX 0.05
- CRMD -0.27
- Stochastic Oscillator
- FAX 80.00
- CRMD 2.12
About FAX abrdn Asia-Pacific Income Fund Inc.
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities, and others.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.